$OSTX

OS Therapies Inc (OSTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 7 ea030148501ex10-1.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is made as of August 10, 2026, by and among OS Therapies Incorporated, a Delaware corporation (“ OSTX ”), OS An

OS Therapies Inc (OSTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 4 ea030084801ex10-1.htm SETTLEMENT AGREEMENT AND MUTUAL RELEASE, DATED AS OF JULY 31, 2026, AMONG OS THERAPIES INCORPORATED, OS ANIMAL HEALTH INC., OS THERAPIES UK LTD AND LEONITE FUND I, LP Exhibit 10.1 SETTLEMENT AGREEMENT AND MUTUAL RELEASE This SETTLEMENT AGREEMENT AN

OS Therapies Inc (OSTX) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. false 0001795091 0001795091 2026-07-23 2026-07-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report

OS Therapies Inc (OSTX) rose about 11% in morning trading after Roth/MKM initiated coverage with a Buy rating and $7.00 price target. The move lifted consensus to four Buys. The article cites upcoming U.S. FDA BLA submission by end-2026 and EMA submission by Sept. 30, 2026, plus recent convertible note funding.

OS Therapies Inc (OSTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 4 ea029686801ex10-1.htm SECURITIES PURCHASE AGREEMENT, DATED AS OF JUNE 30, 2026, AMONG OS THERAPIES INCORPORATED, OS ANIMAL HEALTH INC., OS THERAPIES UK LTD AND LEONITE FUND I, LP Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “ Agreem

OS Therapies (NYSE American: OSTX) appointed Dr. Craig Eagle to its board and said it is preparing for a late Q3 initiation of a confirmatory Phase 3 for OST-HER2. The company secured a $10M line of credit backed by OS Therapies UK tax credits, with an initial $1.6M draw. It expects cash runway into 2027 and targets a U.S. BLA by year-end 2026.

OS Therapies (NYSE American: OSTX) said it will publish four Drug Discovery World articles on OST-HER2 and osteosarcoma. The company also reiterated it will present 2.5-year overall survival data from its Phase 2b OST-HER2 trial at the 2026 ASCO Annual Meeting (May 28–June 2, 2026). It is seeking a U.S. BLA under Accelerated Approval in 2H 2026.

OS Therapies has announced that the European Medicines Agency (EMA) has initiated a rolling review for its OST-HER2 conditional marketing authorization application for osteosarcoma. The company has also achieved alignment with European and Australian regulators on key efficacy endpoints and expects a potential EMA decision in late 2026. Despite a "Neutral" rating from TipRanks' AI Analyst due to weak financial performance, OS Therapies is advancing its oncology pipeline programs.

OS Therapies Inc. (NYSE American: OSTX) announced that its wholly-owned subsidiary, OS Animal Health Corp (OSAH), has filed a Form S-1 with the SEC for an Initial Public Offering, targeting a listing on NYSE American or Nasdaq Capital Markets in the first half of 2026. OS Therapies shareholders are expected to receive one share of OSAH for every ten shares of OS Therapies owned. OSAH will focus on re-establishing and commercializing OST-HER2 for canine osteosarcoma and other HER2-positive cancers, a treatment that has shown improved patient outcomes in canine studies.

OS Therapies announced it raised $7.53 million in gross proceeds from pre-existing investors through warrant exercise inducement and exchange offers. This capital provides runway into 2027 and will fund regulatory approval submissions for OST-HER2, commercial preparation activities, and preparations for an OS Animal Health spinoff. The company aims for regulatory approval of OST-HER2 in the US, UK, and EU in 2026 and plans to file a Biologics Licensing Application with the U.S. FDA by January 2026.